This site is intended for healthcare professionals
The licence for Aclasta (zoledronate) has been extended to include the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.
The recommended dose for the treatment of postmenopausal osteoporosis and osteoporosis in men is a single 5mg intravenous infusion administered once a year.
Further information: Novartis
The most up-to-date drug information at your fingertips.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
Use our constantly updated shortages tracker to check...
Use our timeline to follow the latest coronavirus developments...
New research has linked oral and inhaled steroids to...
Increasing medicines shortages have added more than...
Drugs
Conditions
News and resources
MIMS Hosted